Abstract:Background: Pulmonary arterial hypertension (PAH) is a rare disease characterized by pulmonary vascular remodeling and right heart failure. Specific genetic variants increase the incidence of PAH in carriers with a family history of PAH, those who suffer from certain medical conditions, and even those with no apparent risk factors. Inflammation and immune dysregulation are related to vascular remodeling in PAH, but whether genetic susceptibility modifies the PAH immune response is unclear. TNIP2 and TRAF2 encode for immunomodulatory proteins that regulate NF-κB activation, a transcription factor complex associated with inflammation and vascular remodeling in PAH. Methods: Two unrelated families with PAH cases underwent whole-exome sequencing (WES). A custom pipeline for variant prioritization was carried out to obtain candidate variants. To determine the impact of TNIP2 and TRAF2 in cell proliferation, we performed an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay on healthy lung pericytes transfected with siRNA specific for each gene. To measure the effect of loss of TNIP2 and TRAF2 on NF-kappa-beta (NF-κB) activity, we measured levels of Phospho-p65-NF-κB in siRNA-transfected pericytes using western immunoblotting. Results: We discovered a novel missense variant in the TNIP2 gene in two affected individuals from the same family. The two patients had a complex form of PAH with interatrial communication and scleroderma. In the second family, WES of the proband with PAH and primary biliary cirrhosis revealed a de novo protein-truncating variant in the TRAF2 . The knockdown of TNIP2 and TRAF2 increased NF-κB activity in healthy lung pericytes, which correlated with a significant increase in proliferation over 24 h. Conclusions: We have identified two rare novel variants in TNIP2 and TRAF2 using WES. We speculate that loss of function in these genes promotes pulmonary vascular remodeling by allowing overactivation of the NF-κB signaling activity. Our findings support a role for WES in helping identify novel genetic variants associated with dysfunctional immune response in PAH.

[Genetic, cellular and molecular mechanisms of pulmonary arterial hypertension]

Epigenetic Regulation of Pulmonary Arterial Hypertension

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Molecular genetic framework underlying pulmonary arterial hypertension

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis

Genetic background of pulmonary (vascular) diseases - how much is written in the codes?

Causal associations between telomere length and pulmonary arterial hypertension: A two-sample Mendelian randomization study

Exploring the pathogenesis of pulmonary vascular disease

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical review

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection

Potential Role of Cellular Senescence in Pulmonary Arterial Hypertension

Association between Genotype, Presentation, and Outcome in Childhood Idiopathic and Hereditary Pulmonary Arterial Hypertension

Genetics and precision genomics approaches to pulmonary hypertension

Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development

A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension

Novel TNIP2 and TRAF2 Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension

Deregulation of BMP Signaling in the Pathogenesis of Pulmonary Hypertension